Jounce Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JNCE research report →
Companyjouncetx.com
Jounce Therapeutics, Inc. , a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors.
- CEO
- Kimberlee Cobleigh Drapkin CPA
- IPO
- 2017
- Employees
- 141
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $98.95M
- P/E
- -1.91
- P/S
- 1.21
- P/B
- 0.53
- EV/EBITDA
- 0.83
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -63.71%
- Net Margin
- -62.10%
- ROE
- -25.03%
- ROIC
- -27.05%
Growth & Income
- Revenue
- $82.00M · 204.75%
- Net Income
- $-50,919,000 · 43.97%
- EPS
- $-0.99 · 45.60%
- Op Income
- $-52,242,000
- FCF YoY
- 64.47%
Performance & Tape
- 52W High
- $5.37
- 52W Low
- $0.58
- 50D MA
- $1.64
- 200D MA
- $1.93
- Beta
- 0.75
- Avg Volume
- 3.47M
Get TickerSpark's AI analysis on JNCE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 3, 23 | Concentra Biosciences, LLC | other | 10,000 |
| May 3, 23 | TANG KEVIN C | other | 10,000 |
| May 3, 23 | TANG KEVIN C | other | 5,300,087 |
| May 3, 23 | Concentra Biosciences, LLC | other | 0 |
| May 3, 23 | Salter-Cid Luisa | sell | 7,850 |
| May 3, 23 | Salter-Cid Luisa | sell | 31,400 |
| May 3, 23 | Salter-Cid Luisa | sell | 20,000 |
| May 3, 23 | Raythatha Jigar | sell | 31,400 |
| May 3, 23 | Raythatha Jigar | sell | 20,000 |
| May 3, 23 | MURRAY RICHARD /CA/ | other | 188,778 |
Our JNCE Coverage
We haven't published any research on JNCE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate JNCE Report →